Our partner is a pre-IPO biotech developing first-in-class immunotherapies for autoimmune diseases and cancer through precise elimination or modulation of cytotoxic T and NK cells via KLRG1. They believe this strategy will result in therapeutics with reduced toxicity compared to existing therapeutic approaches for T cell modulation.

This critical hire took ownership of Medical Writing across all programs and was responsible for both hands-on medical writing work and management/selection of contractors. They developed strategy and timelines for document preparation and document review process cross-functionally, across all programs. They also led the development of style standards and guidelines for preparation of regulatory documents submitted to health agencies, as well as reviewed other functional experts’ work for accuracy and consistency in style standards.